Bio-Path Holdings Presents at 2020 American Society of Clinical Oncology Annual Meeting
Bio-Path Holdings, Inc. (BPTH)
Last bio-path holdings, inc. earnings: 11/14 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
biopathholdings.com
Company Research
Source: GlobeNewswire
HOUSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces the presentation of a poster highlighting the clinical trial design of its Phase 2 study of BP1001 (prexigebersen) at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually from May 29-31, 2020. The poster, titled, “A Phase II Study of BP1001 (liposomal Grb2 antisense oligonucleotide) in Patients with Hematologic Malignancies,” was presented virtually by Dr. Maro Ohanian, Department of Leukemia, University of Texas M.D. Anderson Cancer Center. The poster describes the Phase 2 study design of BP1001 (liposomal Grb2 antisense), the Company’s lead drug candidate, in combination with decitabine as a potential treatment for patients diagnosed with acute myeloid leukemia (AML) or high-risk
Show less
Read more
Impact Snapshot
Event Time:
BPTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPTH alerts
High impacting Bio-Path Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
BPTH
News
- Bio-Path Holdings, Inc. (NASDAQ: BPTH) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study [Yahoo! Finance]Yahoo! Finance
- Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswire
- Bio-Path announces $1.2M registered direct offering priced at-the-market [Seeking Alpha]Seeking Alpha
BPTH
Earnings
- 11/14/23 - Beat
BPTH
Sec Filings
- 4/26/24 - Form D
- 4/24/24 - Form S-1
- 4/19/24 - Form 8-K
- BPTH's page on the SEC website